Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 36
Filter
1.
Radiol Case Rep ; 19(4): 1571-1574, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38317705

ABSTRACT

Primary cardiac neoplasms are a rare, commonly benign, tumor with an approximate incidence rate of 0.02%. Papillary fibroelastoma (PFE), a common form of primary cardiac neoplasms, typically present as a mass on the aortic and mitral valves, while rarely presenting as a pulmonary valve tumor. The majority of PFEs are asymptomatic, however valvular masses can pose a significant health hazard due to their potential to fragment into the bloodstream, facilitate thrombus formation, and restrict blood flow. Due to these risks, careful resection of the mass is recommended for symptomatic patients and asymptomatic patients if the tumor is large (>1 cm), mobile, or on left-sided valves. Here we present a case of an incidental finding of a pulmonic valve papillary fibroelastoma in a 65-year-old man by transesophageal echocardiography during a coronary artery bypass graft procedure.

2.
Medicina (Kaunas) ; 56(2)2020 Feb 05.
Article in English | MEDLINE | ID: mdl-32033289

ABSTRACT

Plasma cell features are encountered in a variety of non-plasma cell neoplasias, especially carcinomas of a discohesive type, such as those occurring in the digestive tract and breast. Lobular carcinomas of the breast present themselves in a variety of architectural patterns and many cell morphologies, including plasmacytoid types. A matching plasma cell phenotype is sometimes an associated feature. We report a case of a moderate grade invasive lobular carcinoma with focal plasmacytoid morphology and aberrant expression of plasma cell markers in a patient previously diagnosed with multiple myeloma. Paradoxical plasma cell immunoprofiles can be encountered in many malignancies, causing serious diagnostic problems, even more so with those occurring in discohesive carcinomas in multiple myeloma patients.


Subject(s)
Breast Neoplasms/pathology , Carcinoma, Lobular/pathology , Multiple Myeloma/pathology , Plasma Cells/pathology , Rare Diseases/pathology , Adipose Tissue/pathology , Aged , Antibodies, Neoplasm , Breast Neoplasms/immunology , Carcinoma, Lobular/immunology , Female , Humans , Immunoglobulin kappa-Chains/analysis , Immunohistochemistry , Multiple Myeloma/immunology , Paraffin Embedding/methods , Phenotype , Plasma Cells/immunology , Rare Diseases/immunology , Syndecan-1/analysis
3.
J Extra Corpor Technol ; 47(3): 145-54, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26543248

ABSTRACT

To improve our understanding of the evidence-based literature supporting temperature management during adult cardiopulmonary bypass, The Society of Thoracic Surgeons, the Society of Cardiovascular Anesthesiology and the American Society of ExtraCorporeal Technology tasked the authors to conduct a review of the peer-reviewed literature, including 1) optimal site for temperature monitoring, 2) avoidance of hyperthermia, 3) peak cooling temperature gradient and cooling rate, and 4) peak warming temperature gradient and rewarming rate. Authors adopted the American College of Cardiology/American Heart Association method for development clinical practice guidelines, and arrived at the following recommendation.


Subject(s)
Cardiology/standards , Cardiopulmonary Bypass/standards , Hyperthermia, Induced/standards , Intraoperative Care/standards , Monitoring, Intraoperative/standards , Practice Guidelines as Topic , United States
4.
Ann Thorac Surg ; 100(2): 748-57, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26234862

ABSTRACT

In order to improve our understanding of the evidence-based literature supporting temperature management during adult cardiopulmonary bypass, The Society of Thoracic Surgeons, the Society of Cardiovascular Anesthesiology and the American Society of ExtraCorporeal Technology tasked the authors to conduct a review of the peer-reviewed literature, including: 1) optimal site for temperature monitoring, 2) avoidance of hyperthermia, 3) peak cooling temperature gradient and cooling rate, and 4) peak warming temperature gradient and rewarming rate. Authors adopted the American College of Cardiology/American Heart Association method for development clinical practice guidelines, and arrived at the following recommendations: No Recommendation No recommendation for a guideline is provided concerning optimal temperature for weaning from CPB due to insufficient published evidence.


Subject(s)
Body Temperature , Cardiopulmonary Bypass/standards , Intraoperative Care/standards , Monitoring, Intraoperative/standards , Humans
5.
J Cardiothorac Vasc Anesth ; 29(4): 1104-13, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26279227

ABSTRACT

UNLABELLED: In order to improve our understanding of the evidence-based literature supporting temperature management during adult cardiopulmonary bypass, The Society of Thoracic Surgeons, the Society of Cardiovascular Anesthesiology and the American Society of ExtraCorporeal Technology tasked the authors to conduct a review of the peer-reviewed literature, including: 1) optimal site for temperature monitoring, 2) avoidance of hyperthermia, 3) peak cooling temperature gradient and cooling rate, and 4) peak warming temperature gradient and rewarming rate. Authors adopted the American College of Cardiology/American Heart Association method for development clinical practice guidelines, and arrived at the following recommendations: CLASS I RECOMMENDATIONS: a)The oxygenator arterial outlet blood temperature is recommended to be utilized as a surrogate for cerebral temperature measurement during CPB. (Class I, Level C) b)To monitor cerebral perfusate temperature during warming, it should be assumed that the oxygenator arterial outlet blood temperature under-estimates cerebral perfusate temperature. (Class I, Level C) c)Surgical teams should limit arterial outlet blood temperature to<37°C to avoid cerebral hyperthermia. (Class 1, Level C) d)Temperature gradients between the arterial outlet and venous inflow on the oxygenator during CPB cooling should not exceed 10°C to avoid generation of gaseous emboli. (Class 1, Level C) e)Temperature gradients between the arterial outlet and venous inflow on the oxygenator during CPB rewarming should not exceed 10°C to avoid out-gassing when blood is returned to the patient. (Class 1, Level C) CLASS IIa RECOMMENDATIONS: a)Pulmonary artery or nasopharyngeal temperature recording is reasonable for weaning and immediate post-bypass temperature measurement. (Class IIa, Level C)b)Rewarming when arterial blood outlet temperature ≥30° C: i.To achieve the desired temperature for separation from bypass, it is reasonable to maintain a temperature gradient between arterial outlet temperature and the venous inflow of≤4°C. (Class IIa, Level B) ii.To achieve the desired temperature for separation from bypass, it is reasonable to maintain a rewarming rate≤0.5°C/min. (Class IIa, Level B) NO RECOMMENDATION: No recommendation for a guideline is provided concerning optimal temperature for weaning from CPB due to insufficient published evidence.


Subject(s)
Anesthesiology/standards , Cardiopulmonary Bypass/standards , Extracorporeal Circulation/standards , Practice Guidelines as Topic/standards , Surgeons/standards , Thoracic Surgical Procedures/standards , Anesthesiology/methods , Body Temperature , Cardiopulmonary Bypass/methods , Disease Management , Extracorporeal Circulation/methods , Humans , Hypothermia, Induced/methods , Hypothermia, Induced/standards , Rewarming/methods , Rewarming/standards , Societies, Medical/standards , Thoracic Surgical Procedures/methods , United States
6.
J Cardiothorac Vasc Anesth ; 28(3): 647-51, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24290749

ABSTRACT

OBJECTIVES: Diffuse isolated liver metastases are the dominant mode of tumor progression in a number of cancers and present a major treatment challenge for oncologists. An experimental treatment, percutaneous hepatic perfusion (PHP), utilizes partial venovenous cardiopulmonary bypass to allow administration of high-dose chemotherapy directly and solely to the liver with filtration of chemotherapeutic agents from the blood prior to its return to the systemic circulation, thereby minimizing toxic systemic effects. The following case series describes the management of 5 patients with metastatic melanoma undergoing serial PHPs. DESIGN: A single-center experience from a national multi-center random-assignment trial comparing PHP to best alternative care (BAC) in patients with diffuse melanoma liver metastases. SETTING: A tertiary care hospital. PARTICIPANTS: Five patients with metastatic melanoma to the liver. INTERVENTION: Five patients underwent a total of fifteen PHPs using a venovenous bypass circuit with hemofiltration, receiving hepatic intra-arterial melphalan, 3 mg/kg of ideal body weight, for 30 minutes with a total of 60 minutes of hemofiltration. MEASUREMENTS AND MAIN RESULTS: Five patients tolerated the procedure well with transient hemodynamic and metabolic changes. CONCLUSIONS: In patients with diffuse isolated liver metastases, PHP is a safe and well-tolerated procedure that can be performed more than once and is associated with marked anti-tumor activity in some patients.


Subject(s)
Cardiopulmonary Bypass/methods , Liver Neoplasms/secondary , Melanoma/secondary , Perfusion/methods , Antineoplastic Agents, Alkylating/administration & dosage , Antineoplastic Agents, Alkylating/therapeutic use , Body Temperature/physiology , Catheterization , Female , Hemofiltration , Humans , Liver Circulation , Liver Neoplasms/drug therapy , Liver Neoplasms/surgery , Male , Melanoma/drug therapy , Melanoma/surgery , Melphalan/administration & dosage , Melphalan/therapeutic use , Middle Aged
7.
Med Clin North Am ; 97(6): 1033-50, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24182718

ABSTRACT

Ischemic heart disease (IHD) occurs when myocardial oxygen supply is not adequate for myocardial oxygen demand. Patients with IHD who are undergoing surgery are at risk for development of perioperative cardiac events (PCEs), and this risk depends on the type of surgery, the presence of clinical risk factors, and functional status of the patients. Appropriate perioperative management of medications such as dual antiplatelet therapy and ß-blockers has a significant impact on outcomes. Perioperative management decisions should be communicated clearly between the surgeon, cardiologist, and anesthesiologist in charge of the patient. Appropriate perioperative management reduces the incidence of PCEs.


Subject(s)
Myocardial Ischemia/complications , Myocardial Ischemia/diagnosis , Perioperative Care , Adrenergic alpha-2 Receptor Agonists/therapeutic use , Adrenergic beta-Antagonists/therapeutic use , Angiotensin Receptor Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Calcium Channel Blockers/therapeutic use , Electrocardiography , Humans , Hypolipidemic Agents/therapeutic use , Mineralocorticoid Receptor Antagonists/therapeutic use , Myocardial Ischemia/therapy , Nitrates/therapeutic use , Percutaneous Coronary Intervention , Platelet Aggregation Inhibitors/therapeutic use , Preoperative Care , Risk Assessment , Stents
8.
PLoS One ; 8(11): e79982, 2013.
Article in English | MEDLINE | ID: mdl-24236167

ABSTRACT

Extracellular glutamate is elevated following brain ischemia or trauma and contributes to neuronal injury. We tested the hypothesis that magnesium sulfate (MgSO4, 3 mM) protects against metabolic failure caused by excitotoxic glutamate exposure. Rat cortical neuron preparations treated in medium already containing a physiological concentration of Mg(2+) (1 mM) could be segregated based on their response to glutamate (100 µM). Type I preparations responded with a decrease or small transient increase in oxygen consumption rate (OCR). Type II neurons responded with >50% stimulation in OCR, indicating a robust response to increased energy demand without immediate toxicity. Pre-treatment with MgSO4 improved the initial bioenergetic response to glutamate and ameliorated subsequent loss of spare respiratory capacity, measured following addition of the uncoupler FCCP, in Type I but not Type II neurons. Spare respiratory capacity in Type I neurons was also improved by incubation with MgSO4 or NMDA receptor antagonist MK801 in the absence of glutamate treatment. This finding indicates that the major difference between Type I and Type II preparations is the amount of endogenous glutamate receptor activity. Incubation of Type II neurons with 5 µM glutamate prior to excitotoxic (100 µM) glutamate exposure recapitulated a Type I phenotype. MgSO4 protected against an excitotoxic glutamate-induced drop in neuronal ATP both with and without prior 5 µM glutamate exposure. Results indicate that MgSO4 protects against chronic moderate glutamate receptor stimulation and preserves cellular ATP following treatment with excitotoxic glutamate.


Subject(s)
Magnesium Sulfate/pharmacology , Receptors, Glutamate/metabolism , Adenosine Triphosphate/metabolism , Animals , Cell Respiration/drug effects , Cells, Cultured , Excitatory Amino Acid Antagonists/pharmacology , Glutamic Acid/metabolism , Glutamic Acid/pharmacology , Glycolysis/drug effects , Mitochondria/metabolism , Neurons/drug effects , Neurons/metabolism , Oxygen Consumption , Phenotype , Pyruvic Acid/metabolism , Rats
10.
J Cardiothorac Vasc Anesth ; 27(3): 586-99, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23672862

ABSTRACT

Over the last decade, TECAB has matured into a reproducible technique associated with low incidence of both mortality and morbidity, as well as superior quality of life, when compared with open CABG surgery. However, TECAB also is associated with important and specific challenges for the anesthesiology team, particularly with regard to the physiologic stresses of OLV, placement of special catheters, and induced capnothorax. As the technology supporting robotic surgery evolves and familiarity with, and confidence in, TECAB increases, the authors anticipate increasingly widespread use of these procedures in an increasingly fragile and problematic patient population who will require the support of a skilled and vigilant anesthesiology team.


Subject(s)
Anesthesia , Cardiac Surgical Procedures/methods , Endoscopy/methods , Robotics , Cardiac Surgical Procedures/economics , Cardiac Surgical Procedures/instrumentation , Coronary Artery Disease/surgery , Endoscopy/economics , Endoscopy/instrumentation , Humans , Intraoperative Complications/therapy , Monitoring, Intraoperative , One-Lung Ventilation , Preoperative Care , Robotics/economics , Robotics/instrumentation , Treatment Outcome
12.
Curr Opin Anaesthesiol ; 26(1): 1-5, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23196738

ABSTRACT

PURPOSE OF REVIEW: Tracheobronchial lesions requiring significant resection of the airway have limited surgical options and present significant obstacles to the anesthesiologist and surgeon. This article will review recent advancements in anesthetic and surgical management. RECENT FINDINGS: Technological advances have introduced novel approaches to the patient with large airway lesions. The use of pump-driven and pumpless extracorporeal life support has rapidly expanded and allow for prolonged periods of apneic airway surgery. Tracheal transplantation has advanced from the cadaveric decellularized scaffolds initially used to true synthetic based structures with autologous stem cell derived epithelium. SUMMARY: Significant leaps in tissue engineered airway transplantation have created curative options for patients previously considered inoperable. These patients pose significant challenges to the anesthesiologist during the entire perioperative period. Close collaboration with surgeons and intensivists and the use of recently developed systems for extracorporeal life support are required.


Subject(s)
Anesthesia, General/methods , Anesthesia, Local/methods , Plastic Surgery Procedures/methods , Trachea/surgery , High-Frequency Jet Ventilation/methods , Humans , Intubation, Intratracheal/methods , Life Support Systems , Monitoring, Intraoperative/methods , Respiration, Artificial/methods , Stem Cells , Tissue Engineering/methods , Tissue Scaffolds , Trachea/transplantation
15.
Rom J Morphol Embryol ; 53(2): 299-311, 2012.
Article in English | MEDLINE | ID: mdl-22732799

ABSTRACT

The cellular immunoprofile of cardiac dysfunctions and lesions of ischemic etiology are insufficiently studied to date, especially regarding the contribution of non-cardiomyocytic structures. Aiming to explore this immunoprofile, we used immunohistochemistry applied on embryonic, fetal and adult normal or ischemic myocardium. We observed a decrease of smooth muscle alpha-actin expression in fetal vs. embryonic cardiomyocytes, its absence in normal adult myocardium and its intense expression in the fibrotic scars of ischemic myocardium. DDR2 and vimentin, which are present in the interstitial cells and cardiomyocytes of the embryo, fetus and normal adult heart, are absent in the fibrotic scar tissue and cicatricial infarction, the latter expressing smooth muscle alpha-actin and CD34. This suggested that myofibroblasts and not local fibroblasts that participate in ischemic remodeling. An EGFR-positive vascular network was better represented in the ischemic heart than in the adult normal one, a fact possibly related to EGFR implication in cardiac ischemic pre- and post-conditioning. Therefore, cardiomyocytes and non-cardiomyocytic cells have an undulating immunoprofile according to the intrauterine life stage or age after birth, and a variable contribution in cardiac lesions, mostly in ischemic ones.


Subject(s)
Heart/embryology , Myocardial Ischemia/immunology , Myocardium/immunology , Myocytes, Cardiac/immunology , Age Factors , Desmin/metabolism , Female , Humans , Immunohistochemistry , Immunophenotyping , Infant, Newborn , Male , Middle Aged , Myocardial Ischemia/metabolism , Myocardial Ischemia/pathology , Myocardium/metabolism , Myocardium/pathology , Myocytes, Cardiac/metabolism , Myocytes, Cardiac/pathology , Vimentin/metabolism
17.
Int J Med Robot ; 8(2): 166-8, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22396184

ABSTRACT

BACKGROUND: Patients with spontaneous coronary artery dissection may require surgical revascularization. Reports on the surgical management of this pathology are primarily limited to classic coronary artery bypass grafting via sternotomy on cardiopulmonary bypass, although a limited number of reports of alternatives also exist. METHODS: We describe a case of robotic completely endoscopic coronary surgery using the daVinci® Si™ system in a patient with spontaneous coronary artery dissection. RESULTS: Robotically assisted single left internal mammary artery grafting to the left coronary artery system was carried out successfully in a completely endoscopic fashion. CONCLUSIONS: Selected patients with spontaneous coronary artery dissection may benefit from a totally endoscopic approach to surgical coronary revascularization.


Subject(s)
Aortic Dissection/surgery , Coronary Artery Bypass/methods , Coronary Vessels/physiopathology , Endoscopes , Endoscopy/methods , Minimally Invasive Surgical Procedures/methods , Robotics/methods , Coronary Angiography/methods , Coronary Artery Bypass/instrumentation , Equipment Design , Hemodynamics , Humans , Male , Middle Aged , Minimally Invasive Surgical Procedures/instrumentation , Treatment Outcome
18.
Rom J Morphol Embryol ; 53(1): 41-6, 2012.
Article in English | MEDLINE | ID: mdl-22395498

ABSTRACT

Gastrointestinal stromal tumors (GISTs) are the most common primary mesenchymal neoplasias of the gastrointestinal tract, typically expressing c-kit (CD117) and CD34. Recently, it was reported that nestin and caveolin-1 are also expressed in some human sarcomas, GISTs included. We performed a retrospective study on formalin fixed, paraffin embedded samples from 81 cases of confirmed GISTs, aiming to characterize their immunohistochemical profile, including nestin and caveolin-1 expressions. Tissue samples were evaluated immunohistochemically for CD117, CD34, nestin and caveolin-1. The patients (M:F 36:45), aged 46 to 84 years, had spindle cell type GISTs in 56.7% of cases, epithelioid in 30.8% and mixed pattern in 12.3%. Immunohistochemically, CD117 was positive in 88.9% of GISTs, CD34 in 85.1%, nestin in 77.7% and caveolin-1 in 71.6% of the tumors. Of nine c-kit negative GISTs, 66.7% expressed nestin, the same as caveolin-1 and 44.5% expressed both nestin and caveolin-1. Statistical analysis using Kendall's and Spearman's tests revealed significant correlations between nestin and caveolin-1 expressions (p=0.024). Our results suggest that nestin and caveolin-1 could be considered sensitive markers in GISTs, together with CD117 and CD34, for diagnostic purposes. Their significant expression in CD117 negative GISTs could represent an immunohistochemical alternative in establishing the diagnosis of these tumors.


Subject(s)
Caveolin 1/biosynthesis , Gastrointestinal Stromal Tumors/diagnosis , Gastrointestinal Stromal Tumors/metabolism , Gene Expression Regulation , Intermediate Filament Proteins/biosynthesis , Nerve Tissue Proteins/biosynthesis , Aged , Aged, 80 and over , Antigens, CD34/biosynthesis , Female , Humans , Immunohistochemistry/methods , Male , Middle Aged , Models, Statistical , Nestin , Proto-Oncogene Proteins c-kit/biosynthesis , Retrospective Studies
19.
Rom J Morphol Embryol ; 53(1): 167-71, 2012.
Article in English | MEDLINE | ID: mdl-22395517

ABSTRACT

We report a rare case of renal tumor--mucinous tubular and spindle cell carcinoma in a 65-year-old man. The tumor, located in the right kidney, was well circumscribed. Microscopically, the tumoral proliferation was composed of cuboidal cells arranged in tubules, with abrupt transition to spindle cell morphology in a myxoid stroma. Because of the favorable prognosis with this type of tumor, mucinous tubular and spindle cell carcinoma must be differentiated from papillary renal cell carcinoma, especially the variant with sarcomatoid dedifferentiation.


Subject(s)
Adenocarcinoma, Mucinous/diagnosis , Adenocarcinoma, Mucinous/pathology , Adenocarcinoma/diagnosis , Adenocarcinoma/pathology , Carcinoma/diagnosis , Carcinoma/pathology , Kidney Neoplasms/diagnosis , Kidney Neoplasms/pathology , Aged , Cell Differentiation , Cell Proliferation , Humans , Immunohistochemistry/methods , Kidney/pathology , Male , Medical Oncology/methods , Mitosis , Prognosis , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL